HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Chronic cor pulmonale — Clinical Guidelines

Overview

Chronic cor pulmonale (CCP) is a condition characterized by right ventricular dysfunction secondary to chronic lung diseases, leading to pulmonary hypertension and potential systemic effects. 1 2 3

Diagnosis

Elevated pulmonary artery pressures and right ventricular hypertrophy on echocardiography.

Elevated plasma brain natriuretic peptide (BNP) levels indicative of cardiac strain. 1

Pathological evidence of in situ thrombosis in small pulmonary arteries and arterioles, particularly during exacerbations. 2

Hemodynamic assessment showing increased pulmonary vascular resistance and reduced cardiac output. 3

Management

First-line treatments:

- Hydralazine (25 mg initially, then 50 mg every 6 hours for 48 hours) to reduce pulmonary arteriolar resistance and increase cardiac output. 3

Adjunctive therapies:

- Trimetazidine (20 mg three times daily orally) to improve antioxidant status and potentially lower BNP levels, addressing oxidative stress. 1

Special Populations

No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts.

Key Recommendations

Utilize hydralazine for hemodynamic improvement in patients with chronic cor pulmonale, showing reductions in pulmonary arterial pressure and increased cardiac output. (Evidence: Moderate) 3

Consider trimetazidine to enhance antioxidant defenses and potentially decrease plasma BNP levels in managing oxidative stress in CCP patients. (Evidence: Weak) 1

Regularly assess for in situ thrombosis in small pulmonary vessels during exacerbations of chronic cor pulmonale to guide management strategies. (Evidence: Expert opinion) 2

References

1 Bayram E, Atalay C, Kocatürk H, Yücel O. Effects of trimetazidine on lipid peroxidation, antioxidant enzyme activities and plasma brain natriuretic peptide levels in patients with chronic cor pulmonale. The Journal of international medical research 2005. link 2 Wang C, Du M, Cao D, Weng X, Wu X, Chang Q et al.. A pathological study of in situ thrombosis of small pulmonary arteries and arterioles in autopsy cases of chronic cor pulmonale. Chinese medical journal 1998. link 3 Rubin LJ, Peter RH. Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale. The American journal of cardiology 1981. link90299-x)

Chronic cor pulmonale